Drug Discovery

HiFiBiO Therapeutics buys early-stage biotech firm H-Immune Therapeutics

HiFiBiO Therapeutics has acquired H-Immune Therapeutics, an early-stage biotechnology company engaged in the discovery and development of novel immuno-oncology therapeutics.

Alliqua BioMedical, Adynxx enter into merger deal

Alliqua BioMedical has entered into a merger agreement with Adynxx to create a clinical-stage pharmaceutical firm, which will focus on development of therapies for pain and inflammation.

Carrick licenses global rights to BTG’s ovarian cancer drug

Carrick Therapeutics has acquired global licensing rights to develop and commercialize BTG’s ovarian cancer drug BTG945, which has been renamed as CT900.

Mundipharma buys Spanish biosimilars company Cinfa Biotech

Mundipharma, a global network of privately-owned independent associated companies, has acquired Spanish biosimilars development company Cinfa Biotech from Infarco for an undisclosed price.

Neurocrine Biosciences, Jnana Therapeutics to discover medicines for CNS disorders

Neurocrine Biosciences and Jnana Therapeutics have entered into a research collaboration to discover novel small molecule therapeutics for multiple targets for central nervous system (CNS) disorders.

Inovio develops DNA-encoded monoclonal antibody checkpoint inhibitor

Inovio Pharmaceuticals said that it has completed animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4.

Sitryx launches with $30m funding to develop disease-modifying therapeutics

New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.

Arrowhead, Janssen sign $3.7bn license and collaboration deal

Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.

Boston Pharmaceuticals buys Novartis’ three anti-infective drug candidates

Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.